Hims & Hers Health (NYSE:HIMS) Stock Gets Price Target Trim from Needham & Company LLC

Hims & Hers Health (NYSE:HIMS) had its target price lowered by Needham & Company LLC from $42.00 to $32.00 in a report issued on Tuesday,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Several other research firms have also weighed in on HIMS. Wall Street Zen upgraded shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Truist Financial lifted their price objective on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a “hold” rating in a research note on Monday, August 24th. Deutsche Bank boosted their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th. Weiss Ratings reissued a “sell (d)” rating on shares of Hims & Hers Health in a research note on Wednesday, November 4th. Finally, Morgan Stanley raised their target price on shares of Hims & Hers Health from $21.00 to $28.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus price target of $31.53.

Hims & Hers Health Stock Down 5.1%

Shares of HIMS stock opened at $19.76 on Tuesday. Hims & Hers Health has a 1 year low of $13.74 and a 1 year high of $40.99. The stock has a market cap of $4.61 billion, a PE ratio of -23.81 and a beta of 2.53. The business’s fifty day moving average is $27.77 and its 200-day moving average is $26.75. The company has a debt-to-equity ratio of 3.85, a quick ratio of 0.87 and a current ratio of 0.92.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 9th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.03). Hims & Hers Health had a negative net margin of 6.65% and a negative return on equity of 9.62%. The firm had revenue of $890.37 million during the quarter, compared to analyst estimates of $893.13 million. During the same quarter last year, the company earned $0.06 EPS. The company’s quarterly revenue was up 48.6% compared to the same quarter last year. Equities analysts expect that Hims & Hers Health will post -0.21 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $28.39, for a total transaction of $398,226.53. Following the completion of the sale, the chief operating officer directly owned 456,660 shares of the company’s stock, valued at $12,964,577.40. This represents a 2.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 2,000 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $29.70, for a total value of $59,400.00. Following the sale, the chief financial officer directly owned 234,527 shares of the company’s stock, valued at approximately $6,965,451.90. This represents a 0.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 133,905 shares of company stock valued at $3,826,977 over the last three months. Company insiders own 11.76% of the company’s stock.

Institutional Trading of Hims & Hers Health

A number of hedge funds have recently bought and sold shares of the company. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Hims & Hers Health by 70.0% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after buying an additional 319 shares during the period. Sigma Planning Corp increased its position in shares of Hims & Hers Health by 1.5% in the first quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock worth $540,000 after acquiring an additional 388 shares in the last quarter. Western Wealth Management LLC increased its position in shares of Hims & Hers Health by 6.8% in the third quarter. Western Wealth Management LLC now owns 9,072 shares of the company’s stock worth $270,000 after acquiring an additional 580 shares in the last quarter. Versant Capital Management Inc raised its holdings in shares of Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after acquiring an additional 665 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Hims & Hers Health by 5.1% during the third quarter. Allspring Global Investments Holdings LLC now owns 18,756 shares of the company’s stock valued at $550,000 after acquiring an additional 918 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Latest Hims & Hers Health News

Here’s some of the latest news about HIMS:

• Positive Sentiment: Andrew Huberman’s appointment to the board could support the company’s health and wellness profile. Hims & Hers has also been reported to be preparing a peptide offering, a potential growth opportunity, though its impact is uncertain. Hims & Hers appoints Andrew Huberman as director Hims & Hers peptide offering
• Negative Sentiment: Third-quarter results missed estimates: adjusted EPS was $0.03 versus $0.06 expected, while revenue of about $890 million also came in below consensus. Despite revenue growth of nearly 49% year over year, gross-margin pressure and subscriber declines raised concerns about the quality and cost of that growth. Hims & Hers Q3 earnings miss
• Negative Sentiment: Lower fourth-quarter and 2026 adjusted EBITDA guidance adds to the earnings disappointment, signaling weaker near-term profitability expectations. Hims & Hers earnings guidance

Hims & Hers Health Company Profile

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.